WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 4 fonti

EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos

EMA's CHMP recommends revoking Tavneos' marketing authorization over flawed clinical data, as US approval also hangs in the balance.

Raccontata da

biopharmadive.com

medpagetoday.com

fiercepharma.com

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo15 h fa

EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos

EMA's CHMP recommends revoking Tavneos' marketing authorization over flawed clinical data, as US approval also hangs in the balance.

Timeline cronologica

venerdì 26 giugno 2026·biopharmadive.com
On second try, Acadia drug gets nod from European regulators
The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.
venerdì 26 giugno 2026·endpoints.news
EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos
EMA's CHMP recommends revoking Tavneos' marketing authorization over flawed clinical data, as US approval also hangs in the balance.

fiercepharma.com

13 h fa

Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms

As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators recommending that the ANCA-associated vasculitis drug lose its author | As Amgen prepares…

Leggi questa versione → originale

medpagetoday.com13 h fa

European Regulators Move to Revoke Avacopan Authorization

Trial data 'can no longer be relied upon' to demonstrate drug's efficacy, EMA committee says

Leggi questa versione → originale

biopharmadive.com1 g fa

On second try, Acadia drug gets nod from European regulators

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

Leggi questa versione → originale

venerdì 26 giugno 2026·

medpagetoday.com

European Regulators Move to Revoke Avacopan Authorization

Trial data 'can no longer be relied upon' to demonstrate drug's efficacy, EMA committee says

venerdì 26 giugno 2026·

fiercepharma.com

Europe's CHMP reverses endorsement of Amgen's Tavneos as FDA hearing looms

As Amgen prepares to defend Tavneos’ market approval in the U.S., the company has received a bad omen overseas, with regulators recommending that the ANCA-associated vasculitis…